IL299349A - Preparations for treatment combine with saponin and conjugation of GALNAC and oligonucleotide - Google Patents

Preparations for treatment combine with saponin and conjugation of GALNAC and oligonucleotide

Info

Publication number
IL299349A
IL299349A IL299349A IL29934922A IL299349A IL 299349 A IL299349 A IL 299349A IL 299349 A IL299349 A IL 299349A IL 29934922 A IL29934922 A IL 29934922A IL 299349 A IL299349 A IL 299349A
Authority
IL
Israel
Prior art keywords
xyl
rha
saponin
fuc
group
Prior art date
Application number
IL299349A
Other languages
English (en)
Hebrew (he)
Inventor
Postel Ruben
Hermans Guy
Original Assignee
Sapreme Tech Bv
Postel Ruben
Hermans Guy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/NL2021/050384 external-priority patent/WO2021261992A1/en
Application filed by Sapreme Tech Bv, Postel Ruben, Hermans Guy filed Critical Sapreme Tech Bv
Priority claimed from PCT/NL2021/050394 external-priority patent/WO2021261998A1/en
Publication of IL299349A publication Critical patent/IL299349A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/554—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being a steroid plant sterol, glycyrrhetic acid, enoxolone or bile acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Botany (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
IL299349A 2020-06-24 2021-06-23 Preparations for treatment combine with saponin and conjugation of GALNAC and oligonucleotide IL299349A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
NL2025902 2020-06-24
PCT/NL2021/050384 WO2021261992A1 (en) 2020-06-24 2021-06-18 Conjugate of galnac and saponin, therapeutic composition comprising said conjugate and a galnac-oligonucleotide conjugate
PCT/NL2021/050394 WO2021261998A1 (en) 2020-06-24 2021-06-23 Therapeutic combination of galnac-oligonucleotide conjugate and saponin, and uses thereof

Publications (1)

Publication Number Publication Date
IL299349A true IL299349A (en) 2023-02-01

Family

ID=72087123

Family Applications (1)

Application Number Title Priority Date Filing Date
IL299349A IL299349A (en) 2020-06-24 2021-06-23 Preparations for treatment combine with saponin and conjugation of GALNAC and oligonucleotide

Country Status (6)

Country Link
US (1) US20230293562A1 (cg-RX-API-DMAC10.html)
EP (2) EP4596052A3 (cg-RX-API-DMAC10.html)
JP (2) JP7862331B2 (cg-RX-API-DMAC10.html)
KR (1) KR20230044196A (cg-RX-API-DMAC10.html)
CN (1) CN116194148A (cg-RX-API-DMAC10.html)
IL (1) IL299349A (cg-RX-API-DMAC10.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026060043A1 (en) * 2024-09-10 2026-03-19 Xact Bio, Inc. Compositions and methods for targeting a tissue specific protein expression

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2522213A1 (en) * 2003-04-08 2004-10-28 Dante J. Marciani Semi-synthetic saponin analogs with carrier and immune stimulatory activities for dna and rna vaccines
WO2011054811A1 (en) * 2009-11-03 2011-05-12 Santaris Pharma A/S Rna antagonists targeting hsp27 combination therapy
KR20160083876A (ko) * 2013-11-14 2016-07-12 로슈 이노베이션 센터 코펜하겐 에이/에스 ApoB 안티센스 접합체 화합물
US20220023433A1 (en) * 2018-12-21 2022-01-27 Sapreme Technologies B.V. Saponin Conjugates

Also Published As

Publication number Publication date
EP4596052A2 (en) 2025-08-06
EP4596052A3 (en) 2025-11-05
EP4171643C0 (en) 2025-06-04
JP2026126321A (ja) 2026-08-04
JP7862331B2 (ja) 2026-05-19
EP4171643A1 (en) 2023-05-03
US20230293562A1 (en) 2023-09-21
KR20230044196A (ko) 2023-04-03
JP2023533693A (ja) 2023-08-04
EP4171643B1 (en) 2025-06-04
CN116194148A (zh) 2023-05-30

Similar Documents

Publication Publication Date Title
EP4171641B1 (en) Conjugate of galnac and saponin, therapeutic composition comprising said conjugate and a galnac-oligonucleotide conjugate
EP4355369B1 (en) Conjugate of saponin, oligonucleotide and galnac
WO2022055351A1 (en) Conjugate of saponin, oligonucleotide and galnac
WO2021261998A1 (en) Therapeutic combination of galnac-oligonucleotide conjugate and saponin, and uses thereof
KR20240125934A (ko) 근육 소모 장애를 치료하기 위한 치료적 핵산 및 표적화된 사포닌을 포함하는 조성물
EP4171643B1 (en) Therapeutic combination of galnac-oligonucleotide conjugate and saponin, and uses thereof
EP4210760B1 (en) Conjugate of saponin, oligonucleotide and galnac
AU2021295358B2 (en) Conjugate of galnac and saponin, therapeutic composition comprising said conjugate and a galnac-oligonucleotide conjugate
HK40128805A (en) Therapeutic combination of galnac-oligonucleotide conjugate and saponin, and uses thereof
HK40116734A (en) Conjugate of galnac and saponin, therapeutic composition comprising said conjugate and a galnac oligonucleotide conjugate
HK40124033A (en) Conjugate of saponin, oligonucleotide and galnac
HK40110483A (en) Conjugate of saponin, oligonucleotide and galnac
HK40110483B (en) Conjugate of saponin, oligonucleotide and galnac
HK40129944A (zh) Galnac和皂苷的缀合物、包含所述缀合物和galnac-寡核苷酸缀合物的治疗性组合物
AU2021339332A1 (en) Conjugate of saponin, oligonucleotide and GalNAc
HK40091234B (en) Conjugate of saponin, oligonucleotide and galnac
HK40091234A (en) Conjugate of saponin, oligonucleotide and galnac